title: A novel intrahepatic arterial chemotherapy after radical resection for advanced hepatocellular carcinoma.
abstract: OBJECTIVE
  Advanced hepatocellular carcinoma (HCC) with portal vein invasion and/or intrahepatic metastasis has an unfavorable prognosis even after radical hepatic resection. The aim of this study was to evaluate the effectiveness of a novel postoperative adjuvant chemotherapy given through the hepatic artery and based on biochemical modulation using cisplatin (CDDP) and 5-fluorouracil (5-FU).
  
  
  METHODS
  Fifteen patients with advanced HCC with portal vein invasion into the main trunk and/or intrahepatic metastases of more than 3 segments were included in this study. After radical hepatic resection, the patients were divided to two groups: the adjuvant chemotherapy group (n=7) given the novel arterial infusion regimen with CDDP and 5-FU, and the control group (n=8) given no adjuvant chemotherapy.
  
  
  RESULTS
  Three-year survival rate of the adjuvant chemotherapy group tended to be significantly longer compared to that for the control group (p < 0.05). Most of the tumor recurrence was in the remnant liver, 5 cases in both of the groups. Significant difference of the recurrence patterns was recognized, rather than difference of the disease-free survival rate between the two groups. All of the intrahepatic recurrences are multiple in the control group, but in the adjuvant chemotherapy group, 2 cases of the recurrences showed a localized tumor surgically resected. It is noteworthy that the occurrence of multiple recurrence was significantly later in the adjuvant chemotherapy group compared to the control group (18.9 months vs. 6.5 months; p<0.05).
  
  
  CONCLUSIONS
  Our data suggest that this novel adjuvant chemotherapy can improve the postoperative prognosis of patients with the advanced HCC.
authors.affiliation: Department of Surgery and Science, Graduate School of Medical Sciences Kyushu University, Fukuoka 812-8582, Japan. shinji.msrg@tmd.ac.jp
authors.forename: Shinji
authors.initials: S
authors.lastname: Tanaka
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Shimada
authors.forename: Ken
authors.initials: K
authors.lastname: Shirabe
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Maehara
authors.forename: Norifumi
authors.initials: N
authors.lastname: Harimoto
authors.forename: Eiji
authors.initials: E
authors.lastname: Tsujita
authors.forename: Keishi
authors.initials: K
authors.lastname: Sugimachi
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Maehara
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002408:Catheters, Indwelling; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D007261:Infusions, Intra-Arterial; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011169:Portal Vein / Q000473:pathology; D011379:Prognosis
chemical_list: D002945:Cisplatin; D005472:Fluorouracil